Novo Nordisk Secures Global Rights to Chinese Oral Obesity Candidate

By Meghana Keshavan · STAT News · 2026-09-29

According to reporting from STAT News, Novo Nordisk has acquired an experimental weight-loss pill from Hengrui Pharma for $300 million upfront. The Danish company gains exclusive access to the once-weekly GLP-1/GIP receptor agonist for all markets outside of China as the asset pr

According to reporting from STAT News, Novo Nordisk has acquired an experimental weight-loss pill from Hengrui Pharma for $300 million upfront. The Danish company gains exclusive access to the once-weekly GLP-1/GIP receptor agonist for all markets outside of China as the asset pr